NOTCH3 protein levels identified idiopathic pulmonary arterial hypertension with over 90% accuracy, showing its potential as ...

RCGP chair Victoria Tzortziou Brown talks access; and Dr Keith Hopcroft discusses a report that suggests GPs are not following heart failure referral guidance.

CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...

CVRx’s stock has risen nearly 20% after the company revealed that its heart failure device is set to be investigated in an ...

Ozelle, a global innovator in intelligent diagnostics, will showcase its next-generation solution at WHX Labs Dubai 2026 (Feb ...

Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is ...

NT-proBNP is a cornerstone biomarker in the diagnosis and management of heart failure. Despite its widespread use, important biological and analytical challenges remain. One of the most sign ...

Orphai Therapeutics Inc. ('Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for ...

A collaborative study from the MRC Laboratory of Medical Sciences (LMS) and Imperial College London has found that the protein ACE2 may play a ...

NT-proBNP testing should become compulsory for referring patients to specialist heart failure services to improve diagnosis of the condition in primary care, an expert report has said. The Alliance ...